Update on Sales in USA
Cizzle Biotechnology Holdings PLC announced that its North American licensing partner, Cizzle Bio Inc., has launched its CIZ1B Biomarker Blood Test for Lung Cancer in the Dallas-Fort Worth and San Antonio metropolitan areas of Texas. This commercial roll-out follows successful laboratory validation and CLIA approval at OmniHealth Diagnostics. Cizzle Bio plans to expand physician access through additional CLIA-certified laboratory partners across the United States in the coming months, aiming for nationwide testing coverage and rapid uptake.
Select text to share a quote on X · sign in to keep highlights & notes in your CIZ notes
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to note that the Company's North American licensing partner Cizzle Bio Inc ("BIO"), has today announced the availability of the Company's proprietary CIZ1B Biomarker Blood Test for Lung Cancer (the "Test") for sale to licensed healthcare providers across the Dallas-Fort Worth and San Antonio metropolitan areas in Texas. BIO selected the Dallas-Fort Worth and San Antonio markets for their initial full commercial roll-out because of their large at-risk populations, strong physician networks and strategic importance to their commercialisation plans.
As announced on 16 June 2026, the Test has successfully completed laboratory validation and is now approved for use under Clinical Laboratory Improvement Amendments ("CLIA") at OmniHealth Diagnostics ("OmniHealth"). The commercial launch in Texas follows BIO having completed its initial commercial readiness programme and limited targeted commercial sales. BIO expect to expand physician access to the Test in the coming months through additional CLIA-certified laboratory partners across the United States.
The full BIO press release can be read here: http://www.rns-pdf.londonstockexchange.com/rns/4008N_1-2026-7-22.pdf
Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:
"With accreditation and initial logistics in place to manage expected demand, BIO is now focused on the marketing and deployment of the CIZ1B biomarker test to enable US nationwide testing coverage. The strategic decision to commence full commercial sales in such a populous area of the USA should provide an excellent base to achieve rapid uptake and serve as a model to increase capacity in other areas of the U.S., Canada and the Caribbean in the short term."
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.